If you have been reading about c-Met signaling and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The short length of pompilidotoxins implies that the crucial amino acid for receptor binding would be easier to detect in studies based on pompilidotoxins. Additionally, the binding of the α-scorpion or sea anemone toxin to the sodium receptor also includes a complex system of forming three to four additional disulfide bonds. Pompilidotoxins cannot form such bonds. Pompilidotoxins thus provide a special advantage to research, classify, and characterise different isoforms of sodium channels due to their concise and simple structure. They have already been used for neuronal research into the action mechanisms of sodium channels, and the characterisation of receptor functions. Knowing more about the working of sodium channels could greatly contribute to healthcare as sodium channel alterations are associated with a large range of neurological disorders. Persistent sodium currents are especially participating in some variants of epilepsy and MS. Moreover, β-PMTX itself has been associated with being an epilepsy-inducing agent due to its drastic working in increasing neuronal excitability and has been recognized as being especially important for providing insights into the role of sodium currents in epileptogenesis. Thus, even though pompilidotoxins are not used as drugs and therefore have no efficacious nor adverse effects, they are medically valuable as a research model to indirectly improve patient well-being.
This practice can make drugs of otherwise indispensably potent value more tolerable to certain patients and spare them needless suffering, hence-reducing the overall side-effect burden or concern thereof. Although clomipramine shows around 100- to 200-fold preference in affinity for the serotonin transporter (SERT) over the norepinephrine transporter (NET), its major active metabolite, desmethylclomipramine (norclomipramine), binds to the NET with very high affinity (Ki = 0.32 nM) and with dramatically reduced affinity for the SERT (Ki = 31.6 nM). Moreover, desmethylclomipramine circulates at concentrations that are approximately twice those of clomipramine. In accordance, occupancy of both the SERT and the NET has been shown with clomipramine administration in positron emission tomography studies with humans and non-human primates. As such, clomipramine is in fact a fairly balanced SNRI rather than only a serotonin reuptake inhibitor (SRI). The antidepressant effects of clomipramine are thought to be due to reuptake inhibition of serotonin and norepinephrine, while serotonin reuptake inhibition only is thought to be responsible for the effectiveness of clomipramine in the treatment of OCD. Conversely, antagonism of the H1, α1-adrenergic, and muscarinic acetylcholine receptors is thought to contribute to its side effects. Blockade of the H1 receptor is specifically responsible for the antihistamine effects of clomipramine and side effects like sedation and somnolence (sleepiness).
Allylprodine is an opioid analgesic that is an analog of prodine. It was discovered by Hoffman-La Roche in 1957 during research into the related drug pethidine. Derivatives were tested to prove the theory that phenolic and non-phenolic opioids bind at different sites of the opiate receptor. Allylprodine is more potent as an analgesic than similar drugs such as α-prodine, and the 3R,4S-isomer is 23 times more potent than morphine, due to the allyl group binding to an additional amino acid target in the binding site on the μ-opioid receptor. It is also stereoselective, with one isomer being much more active. When modeled in three dimensions, the alkene overlays the alkenes found in 14-cinnamoyloxycodeinone and in 14-allyloxycodeinone, re-enforcing the presence of an interaction of the alkene. Allylprodine produces similar effects to other opioids, such as analgesia and sedation, along with side effects such as nausea, itching, vomiting and respiratory depression which may be harmful or fatal.
2021 meta-analyses of trials over periods of 1 to 28 months found limited evidence to indicate that lifestyle modifications and nutritional supplementation affect mortality, liver cirrhosis, liver decompensation, liver transplantation, and hepatocellular carcinoma in people with non-alcohol-related fatty liver disease; authors said that it was unlikely that differences in clinical outcomes would become apparent in trials with less than 5 years to 10 years of follow‐up, and that sample sizes needed to be much larger than had been used.
Sources: en.wikipedia.org
South African military decorations Military history of South Africa Conscription in South Africa South African military ranks South African National Defence Force South African Police South West African Territorial Force (SWATF)
== Further reading == Liu, Shuchang; Liu, Feng; Jia, Haihong; Yan, Yan; Wang, Hongfang; Guo, Xingqi; Xu, Baohua (2016). "A glutathione S-transferase gene associated with antioxidant properties isolated from Apis cerana cerana". The Science of Nature. 103 (5–6): 43. Bibcode:2016SciNa.103...43L. doi:10.1007/s00114-016-1362-3. PMID 27126403. S2CID 17260700. Hinchman, Cheri A.; Ballatori, Nazzareno (1994). "Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process". Journal of Toxicology and Environmental Health. 41 (4): 387–409. Bibcode:1994JTEHA..41..387H. doi:10.1080/15287399409531852. PMID 8145281.
=== Oncological research === In January 2026, a perspective piece in The EMBO Journal proposed mechanistic parallels between cancer cell behavior and helminth (parasitic) infections, specifically regarding immune evasion, migration, and immune modulation. The piece suggested that because cancer cells and helminths share these biological strategies, anthelmintic drugs like ivermectin may be candidates for therapeutic repurposing. The proposed mechanism involves utilizing the drug's known antiparasitic action to disrupt oncogenic pathways and potentially trigger immunogenic responses in the host environment. While these theoretical frameworks and preclinical models identify ivermectin as a potential adjunct in cancer therapy, clinical efficacy in humans has not been established, and the research remains in the investigational phase.
Sources: en.wikipedia.org
===== MeSH D08.811.682.667 – oxidoreductases acting on sulfur group donors ===== MeSH D08.811.682.667.061 – dihydrolipoamide dehydrogenase MeSH D08.811.682.667.076 – ferredoxin-nadp reductase MeSH D08.811.682.667.092 – glutathione reductase MeSH D08.811.682.667.124 – hydrogensulfite reductase MeSH D08.811.682.667.186 – protein-disulfide reductase (glutathione) MeSH D08.811.682.667.217 – sulfite dehydrogenase MeSH D08.811.682.667.249 – sulfite oxidase MeSH D08.811.682.667.374 – sulfite reductase (ferredoxin) MeSH D08.811.682.667.500 – sulfite reductase (nadph) MeSH D08.811.682.667.750 – thioredoxin reductase (nadph)
== Function and mechanism == "SARS" and its enzyme product seryl-tRNA synthetase are involved in protein translation; specifically, seryl-tRNA synthetase catalyses the transfer of L-serine to tRNA (Ser). The cytosolic enzyme recognises its cognate tRNA species and binds with a high level of specificity, allowing the accurate interaction between corresponding codons and anticodons on mRNA and tRNA during protein translation.
== Safety and regulations == PVDF is widely considered safe and ubiquitous used for water treatment, the food industry, and biocompatible devices like hernia meshes or internal devices. PVDF differs from PFAS in that alternating groups are hydrogen, making it less resilient to high temperatures, but also meaning that byproducts don't degrade into known hazardous PFAS. However, studies examining ecotoxity have shown that very high concentrations (up to 100 mg/L) may alter jellyfish behavior, while not being toxic to them. In the US, FDA regulations consider PVDF to be food safe, while US EPA water treatment regulations on PFAS have avoided placing limits on PVDF, while strictly limit concentrations of PFAS. PVDF was added to the Living Building Challenge (LBC) Red List in 2022. The Red List bans substances prevalent in the building industry that pose serious risks to human health and the environment from construction that seeks to meet the criteria of the Living Building Challenge (LBC). Proposed regulations in the EU aim to ban "any substance that contains at least one fully fluorinated methyl (-CF3) or methylene (-CF2-) carbon atom (without any H/Cl/Br/I attached to it)". Unless exemptions are made, the application of inconsistent and severe regulations may propose an existential risk to the industry.
Yvonne Frances Rawsthorne. Operational Readiness Senior Officer, HM Revenue and Customs. For Public Service. Iain Robert Reeve. Head of Ukraine Rail Response Team, Department for Transport. For services to Rail Aid in Ukraine. Carole Patricia Richardson. Lately Chair, Rossie Young People's Trust. For services to Young People. Dr. Gordon Cameron Richardson. Treasurer, Walking Alliance. For services to Disability Access. Luke Thomas Rigg, JP. Lead Diversity and Community Relations Magistrate for England and Wales. For services to Diversity in the Judiciary. Gaynor Jean Ripley. Partnership Manager, Department for Work and Pensions. For Public Service. Fiona Roberts, JP. Magistrate, Cornwall Bench, South West Region. For services to the Magistracy and the Administration of Justice. Kathryn Rose Roberts. Chief Executive Officer, Association of Mental Health Providers. For services to Mental Health. Elaine Linda Robinson. Founder Member, Parents of Oldham InTouch and Oldham Special Educational Needs and Disabilities Support Service. For services to Children with Special Educational Needs and Disabilities. Lesley Robinson. Managing Director, First Class Supply and Tutoring Ltd. For services to Education. Rebecca Robson. Founder, Women's Community Matters. For services to the Victims of Domestic Abuse. Simon Rogan. Chef, L'Enclume. For services to the Food Industry. Patricia Mary Rogers. Co-Founder, Every Action Has Consequences. For services to Young People. Samuel Ross. Artist, Designer and Creative Director. For services to Fashion. Ian Alexander Russell.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.